Bionano Current Deferred Revenue vs Other Current Liab Analysis

BNGO Stock

USD 0.26 0.02 8.33%

Bionano Genomics financial indicator trend analysis is way more than just evaluating Bionano Genomics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bionano Genomics is a good investment. Please check the relationship between Bionano Genomics Current Deferred Revenue and its Other Current Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.

Current Deferred Revenue vs Other Current Liab

Current Deferred Revenue vs Other Current Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bionano Genomics Current Deferred Revenue account and Other Current Liab. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Bionano Genomics' Current Deferred Revenue and Other Current Liab is 0.86. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Bionano Genomics, assuming nothing else is changed. The correlation between historical values of Bionano Genomics' Current Deferred Revenue and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Bionano Genomics are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Current Deferred Revenue i.e., Bionano Genomics' Current Deferred Revenue and Other Current Liab go up and down completely randomly.

Correlation Coefficient

0.86

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Other Current Liab

Most indicators from Bionano Genomics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bionano Genomics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.At this time, Bionano Genomics' Tax Provision is very stable compared to the past year. As of the 29th of November 2024, Selling General Administrative is likely to grow to about 98.2 M, while Enterprise Value Over EBITDA is likely to drop (0.62).

	2021	2022	2023	2024 (projected)
Interest Expense	927K	298K	5.1M	5.4M
Depreciation And Amortization	4.0M	10.1M	13.7M	14.4M

Interest Expense Depreciation And Amortization

Bionano Genomics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Inventory	Other Current Assets	Other Stockholder Equity
Total Assets		0.33	0.63	0.47	0.98	0.79	0.95	0.8	0.84	0.22	-0.67	0.94	0.36	0.95	0.01	0.72	0.96	0.67	0.85	0.86	0.72	-0.35	0.86	0.8	0.82	0.17
Short Long Term Debt Total	0.33		0.4	0.93	0.24	0.73	0.54	0.74	0.4	0.84	-0.89	0.48	0.48	0.29	0.5	0.55	0.29	0.66	0.76	0.75	0.55	-0.43	0.75	0.65	0.74	0.15
Other Current Liab	0.63	0.4		0.58	0.5	0.77	0.51	0.78	0.86	0.54	-0.68	0.76	-0.16	0.77	0.54	0.39	0.42	0.56	0.64	0.69	0.39	0.13	0.67	0.82	0.76	0.4
Total Current Liabilities	0.47	0.93	0.58		0.36	0.88	0.64	0.87	0.54	0.94	-0.95	0.62	0.23	0.47	0.59	0.53	0.39	0.75	0.79	0.83	0.53	-0.35	0.84	0.8	0.84	0.22
Total Stockholder Equity	0.98	0.24	0.5	0.36		0.71	0.92	0.72	0.77	0.08	-0.58	0.89	0.41	0.92	-0.12	0.69	0.96	0.59	0.79	0.79	0.69	-0.4	0.8	0.73	0.74	0.1
Other Liab	0.79	0.73	0.77	0.88	0.71		0.86	1.0	0.82	0.75	-0.95	0.87	0.2	0.81	0.51	0.59	0.68	0.77	0.92	0.97	0.59	-0.3	0.97	0.96	0.98	0.19
Net Tangible Assets	0.95	0.54	0.51	0.64	0.92	0.86		0.86	0.76	0.39	-0.78	0.88	0.48	0.85	0.13	0.72	0.95	0.69	0.91	0.92	0.72	-0.46	0.93	0.8	0.86	0.13
Property Plant And Equipment Net	0.8	0.74	0.78	0.87	0.72	1.0	0.86		0.83	0.73	-0.95	0.88	0.24	0.82	0.49	0.62	0.7	0.76	0.94	0.98	0.62	-0.3	0.97	0.97	0.99	0.24
Current Deferred Revenue	0.84	0.4	0.86	0.54	0.77	0.82	0.76	0.83		0.4	-0.7	0.86	0.13	0.89	0.32	0.55	0.71	0.59	0.77	0.81	0.55	-0.19	0.79	0.85	0.83	0.37
Net Debt	0.22	0.84	0.54	0.94	0.08	0.75	0.39	0.73	0.4		-0.81	0.39	-0.06	0.26	0.77	0.23	0.12	0.59	0.55	0.63	0.23	-0.13	0.63	0.65	0.66	0.2
Retained Earnings	-0.67	-0.89	-0.68	-0.95	-0.58	-0.95	-0.78	-0.95	-0.7	-0.81		-0.8	-0.37	-0.68	-0.47	-0.69	-0.57	-0.83	-0.93	-0.95	-0.69	0.43	-0.95	-0.91	-0.96	-0.16
Accounts Payable	0.94	0.48	0.76	0.62	0.89	0.87	0.88	0.88	0.86	0.39	-0.8		0.31	0.96	0.1	0.81	0.83	0.83	0.89	0.9	0.81	-0.38	0.91	0.91	0.9	0.19
Cash	0.36	0.48	-0.16	0.23	0.41	0.2	0.48	0.24	0.13	-0.06	-0.37	0.31		0.19	-0.37	0.69	0.46	0.35	0.54	0.42	0.69	-0.7	0.42	0.18	0.33	-0.11
Non Current Assets Total	0.95	0.29	0.77	0.47	0.92	0.81	0.85	0.82	0.89	0.26	-0.68	0.96	0.19		0.08	0.67	0.83	0.67	0.82	0.84	0.67	-0.27	0.84	0.88	0.85	0.2
Non Currrent Assets Other	0.01	0.5	0.54	0.59	-0.12	0.51	0.13	0.49	0.32	0.77	-0.47	0.1	-0.37	0.08		-0.28	-0.07	0.07	0.25	0.35	-0.28	0.41	0.31	0.38	0.38	0.18
Long Term Debt	0.72	0.55	0.39	0.53	0.69	0.59	0.72	0.62	0.55	0.23	-0.69	0.81	0.69	0.67	-0.28		0.68	0.85	0.79	0.72	1.0	-0.7	0.75	0.65	0.7	0.11
Cash And Short Term Investments	0.96	0.29	0.42	0.39	0.96	0.68	0.95	0.7	0.71	0.12	-0.57	0.83	0.46	0.83	-0.07	0.68		0.56	0.78	0.78	0.68	-0.37	0.78	0.64	0.69	0.14
Net Receivables	0.67	0.66	0.56	0.75	0.59	0.77	0.69	0.76	0.59	0.59	-0.83	0.83	0.35	0.67	0.07	0.85	0.56		0.76	0.77	0.85	-0.63	0.82	0.79	0.8	-0.04
Common Stock Total Equity	0.85	0.76	0.64	0.79	0.79	0.92	0.91	0.94	0.77	0.55	-0.93	0.89	0.54	0.82	0.25	0.79	0.78	0.76		0.99	0.79	-0.46	0.98	0.91	0.96	0.21
Common Stock Shares Outstanding	0.86	0.75	0.69	0.83	0.79	0.97	0.92	0.98	0.81	0.63	-0.95	0.9	0.42	0.84	0.35	0.72	0.78	0.77	0.99		0.72	-0.4	0.99	0.94	0.98	0.22
Long Term Debt Total	0.72	0.55	0.39	0.53	0.69	0.59	0.72	0.62	0.55	0.23	-0.69	0.81	0.69	0.67	-0.28	1.0	0.68	0.85	0.79	0.72		-0.7	0.75	0.65	0.7	0.11
Non Current Liabilities Total	-0.35	-0.43	0.13	-0.35	-0.4	-0.3	-0.46	-0.3	-0.19	-0.13	0.43	-0.38	-0.7	-0.27	0.41	-0.7	-0.37	-0.63	-0.46	-0.4	-0.7		-0.47	-0.33	-0.4	0.33
Capital Surpluse	0.86	0.75	0.67	0.84	0.8	0.97	0.93	0.97	0.79	0.63	-0.95	0.91	0.42	0.84	0.31	0.75	0.78	0.82	0.98	0.99	0.75	-0.47		0.94	0.98	0.15
Inventory	0.8	0.65	0.82	0.8	0.73	0.96	0.8	0.97	0.85	0.65	-0.91	0.91	0.18	0.88	0.38	0.65	0.64	0.79	0.91	0.94	0.65	-0.33	0.94		0.98	0.22
Other Current Assets	0.82	0.74	0.76	0.84	0.74	0.98	0.86	0.99	0.83	0.66	-0.96	0.9	0.33	0.85	0.38	0.7	0.69	0.8	0.96	0.98	0.7	-0.4	0.98	0.98		0.2
Other Stockholder Equity	0.17	0.15	0.4	0.22	0.1	0.19	0.13	0.24	0.37	0.2	-0.16	0.19	-0.11	0.2	0.18	0.11	0.14	-0.04	0.21	0.22	0.11	0.33	0.15	0.22	0.2

Click cells to compare fundamentals

Bionano Genomics Account Relationship Matchups

Bionano Genomics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	30.2M	60.4M	377.1M	307.5M	214.4M	142.9M
Short Long Term Debt Total	20.0M	36.4M	10.7M	11.7M	79.4M	83.4M
Other Current Liab	3.2M	5.6M	7.9M	17.4M	16.3M	9.4M
Total Current Liabilities	26.3M	8.9M	21.8M	35.9M	100.0M	105.0M
Total Stockholder Equity	3.6M	35.1M	337.1M	249.4M	96.2M	89.9M
Other Liab	227.1K	97.9K	9.2M	13.1M	15.1M	15.8M
Net Tangible Assets	3.6M	26.4M	337.1M	172.1M	197.9M	207.8M
Property Plant And Equipment Net	1.9M	4.9M	20.9M	29.0M	32.5M	34.1M
Current Deferred Revenue	357.5K	415.5K	684K	871K	783K	555.6K
Net Debt	2.7M	(22.1M)	(13.9M)	6.6M	61.5M	64.5M
Retained Earnings	(102.6M)	(143.7M)	(216.1M)	(348.7M)	(581.2M)	(552.1M)
Accounts Payable	2.7M	2.9M	9.7M	12.5M	10.4M	5.9M
Cash	17.3M	38.4M	24.6M	5.1M	17.9M	17.3M
Non Current Assets Total	1.9M	13.7M	104.7M	150.2M	74.3M	48.6M
Non Currrent Assets Other	(1.9M)	102.6K	749K	2.8M	7.4M	7.8M
Cash And Short Term Investments	17.3M	38.4M	250.6M	113.2M	101.9M	74.8M
Net Receivables	6.3M	2.8M	4.9M	7.0M	9.7M	5.6M
Common Stock Total Equity	3.4K	19.0K	29K	30K	34.5K	36.2K
Common Stock Shares Outstanding	1.5M	10.4M	27.7M	28.9M	34.2M	35.9M
Liabilities And Stockholders Equity	30.3M	60.4M	377.1M	307.5M	214.4M	142.9M
Non Current Liabilities Total	335.0K	16.4M	18.1M	22.2M	18.2M	16.2M
Capital Surpluse	106.2M	178.7M	553.7M	599.2M	689.1M	723.5M
Inventory	3.4M	3.3M	12.4M	29.8M	22.9M	24.0M
Other Current Assets	1.2M	2.2M	4.5M	7.3M	7.1M	7.5M
Other Stockholder Equity	106.2M	178.7M	553.7M	599.2M	677.3M	711.2M
Total Liab	26.6M	25.4M	40.0M	58.1M	118.2M	124.2M
Property Plant And Equipment Gross	1.9M	4.9M	10.3M	29.0M	51.6M	54.1M
Total Current Assets	28.3M	46.8M	272.4M	157.3M	140.1M	94.3M
Non Current Liabilities Other	808.4K	44.5K	18.0M	22.1M	10.9M	8.4M
Common Stock	3.4K	19.0K	29K	30K	5K	4.8K
Property Plant Equipment	1.9M	4.9M	10.3M	18.0M	20.7M	21.8M
Net Invested Capital	23.7M	51.4M	337.1M	249.4M	166.0M	126.2M
Net Working Capital	1.9M	37.8M	250.6M	121.4M	40.1M	72.4M
Retained Earnings Total Equity	(102.6M)	(143.7M)	(216.1M)	(348.7M)	(313.8M)	(298.2M)
Deferred Long Term Liab	182.6K	97.9K	146K	127K	114.3K	137.3K

Pair Trading with Bionano Genomics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bionano Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bionano Genomics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Bionano Stock

0.69	A	Agilent Technologies	Pair Corr
0.89	ME	23Andme Holding	Pair Corr
0.85	VALN	Valneva SE ADR	Pair Corr

Moving against Bionano Stock

0.85	DRUG	Bright Minds Biosciences	Pair Corr
0.78	VCYT	Veracyte	Pair Corr
0.72	VERA	Vera Therapeutics	Pair Corr
0.53	VANI	Vivani Medical	Pair Corr
0.48	VCEL	Vericel Corp Ord	Pair Corr

The ability to find closely correlated positions to Bionano Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bionano Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bionano Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bionano Genomics to buy it.

The correlation of Bionano Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bionano Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bionano Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Bionano Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Bionano Genomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bionano Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionano Genomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionano Genomics Stock:

How To Invest In Bionano

Details

Is Bionano Stock a good investment?

Details

What is Bionano Genomics' Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.

You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.30)

Revenue Per Share

0.749

Quarterly Revenue Growth

(0.10)

Return On Assets

(0.33)

Return On Equity

(1.38)

The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bionano Current Deferred Revenue vs Other Current Liab Analysis

Current Deferred Revenue vs Other Current Liab

Current Deferred Revenue vs Other Current Liab Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Other Current Liab

Bionano Genomics fundamental ratios Correlations

Bionano Genomics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bionano Genomics fundamental ratios Accounts

Pair Trading with Bionano Genomics

Moving together with Bionano Stock

Moving against Bionano Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Net	+ 1.0	Other Liab
Long Term Debt Total	+ 1.0	Long Term Debt
Other Current Assets	+ 0.99	Property Plant And Equipment Net
Common Stock Shares Outstanding	+ 0.99	Common Stock Total Equity
Capital Surpluse	+ 0.99	Common Stock Shares Outstanding
Total Stockholder Equity	+ 0.98	Total Assets

Other Current Assets	- 0.96	Retained Earnings
Capital Surpluse	- 0.95	Retained Earnings
Common Stock Shares Outstanding	- 0.95	Retained Earnings
Retained Earnings	- 0.95	Property Plant And Equipment Net
Retained Earnings	- 0.95	Other Liab
Retained Earnings	- 0.95	Total Current Liabilities